Advertisement Valeant launches zelaCARD program for patients taking Zelapar - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Valeant launches zelaCARD program for patients taking Zelapar

Valeant Pharmaceuticals North America has introduced a rebate program for Parkinson's disease patients with a Zelapar orally disintegrating tablets prescription. The zelaCARD, a rebate card provided to patients, can offer savings to patients regardless of their prescription drug benefit coverage.

The zelaCARD, which is similar in size to a credit card, is given to the pharmacist at the time a Zelapar prescription is filled. If the patient uses a mail-in prescription program, a form is available with the zelaCARD to send in along with the prescription. The patient is entitled to receive up to a $40 rebate per prescription, or up to a $480 value per year.

Wes Wheeler, president of Valeant Pharmaceuticals said: “With more than 1.5 million Americans suffering from Parkinson’s disease, we are not only looking for new ways to treat patients, but also ways to ease the financial burden of their disease. The zelaCARD is one way we are working to improve patients’ access to treatment.”